 After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation NASDAQ: AGTC has run into safety problems. The Company recently enrolled six pediatric achromatopsia ACHM with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a. 